← Back to Search

Other

FF-10101-01 for Acute Myeloid Leukemia

Phase 1 & 2
Waitlist Available
Research Sponsored by Fujifilm Pharmaceuticals U.S.A., Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests FF-10101-01, a new oral drug, in patients with a specific type of blood cancer. The drug aims to block signals in cancer cells to stop or slow their growth.

Eligible Conditions
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Phase 1/2a: Frequency of adverse events
Secondary study objectives
Phase 1/2a: Composite complete remission rate (CRc) including CR
Phase 1/2a: Frequency of Adverse events including assessment of 12 lead ECG.
Phase 1/2a: Frequency of Adverse events including assessment of vital signs
+24 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

11Treatment groups
Experimental Treatment
Group I: Cohort 8: 225 mgExperimental Treatment1 Intervention
Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group II: Cohort 7: 150 mgExperimental Treatment1 Intervention
Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group III: Cohort 6: 100 mgExperimental Treatment1 Intervention
Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group IV: Cohort 5: 75 mgExperimental Treatment1 Intervention
Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group V: Cohort 4: 50 mgExperimental Treatment1 Intervention
Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group VI: Cohort 3: 35 mgExperimental Treatment1 Intervention
Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group VII: Cohort 2: 20 mgExperimental Treatment1 Intervention
Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group VIII: Cohort 22: 100 mgExperimental Treatment1 Intervention
Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group IX: Cohort 21: 75 mgExperimental Treatment1 Intervention
Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group X: Cohort 20: 50 mgExperimental Treatment1 Intervention
Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Group XI: Cohort 1: 10 mgExperimental Treatment1 Intervention
Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FF-10101-01
2017
Completed Phase 2
~100

Find a Location

Who is running the clinical trial?

Fujifilm Pharmaceuticals U.S.A., Inc.Lead Sponsor
8 Previous Clinical Trials
569 Total Patients Enrolled
~11 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top